medigraphic.com

2014, Número 3

<< Anterior Siguiente >>

Rev Cuba Endoc 2014; 25 (3)


Conducta ante un incidentaloma suprarrenal

Turcios TSE, Cabrera GM, Torres PR

Idioma: Español
Referencias bibliográficas: 46
Paginas: 243-252
Archivo PDF: 116.38 Kb.


RESUMEN

El incidentaloma suprarrenal en la actualidad es uno de los dilemas diagnósticoterapéuticos mas frecuentes en la Endocrinología. Tiene un pico de aparición entre los 50 y los 70 años de edad, y se asocia a una mayor frecuencia de obesidad, diabetes mellitus e hipertensión arterial. La etiología es diversa, pero alrededor del 80 % son adenomas benignos no funcionantes. A pesar de ello, la aparición de un carcinoma (por su agresividad) y disfunción hormonal (por la repercusión desfavorable sobre algunos factores de riesgo cardiovascular y el sistema óseo), pueden ensombrecer el pronóstico. La conducta estará basada en las definiciones mencionadas: naturaleza y función, y las 2 modalidades más empleadas son la cirugía adrenal (de preferencia laparoscópica, excepto si el tumor tiene criterios imagenológicos de malignidad); y la conservadora, que conlleva un seguimiento de, al menos, 5 años. El conocimiento de sus características, puede favorecer el mejor tratamiento a los pacientes con diagnóstico de un tumor suprarrenal incidental, y la garantía de una mejor calidad de vida.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Libe R, Dall Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B. Longterm follow-up study of patients with adrenal incidentaloma. Eur J Endocrinol. 2002;147:489-94.

  2. Salmerón de Diego J. Tumores suprarrenales clínicamente asintomáticos (incidentalomas suprarrenales). Rev Endocrinol Nutr. 2001;48(2):39-47.

  3. Mantero F, Terzolo M, Arnaldi G. A survey on adrenal incidentaloma in Italy. Study Group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85:637-44.

  4. Audenet F, Méjean A, Chartier E, Rouprét M. Adrenal tumours are more predominant in females regardles of their histological subtype: a review. World J Urol. 2013;31:1037-43.

  5. Mansman G, Lan J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25:309-40.

  6. Androulakis I, Kaltsas G, Piaditis G, Grossman A. The clinical significance of adrenal incidentaloma. Eur J Clin Invest. 2011;41(5):552-60.

  7. Barzón L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149:273-85.

  8. Ito T, Imai T, Kikumori T, Shibata A, Horiba J, Kobayashi H, et al. Adrenal incidentaloma: review of 197 patients and report of a drug- related false positive urinary normetanephrine result. Surg Today. 2006;36:961-5.

  9. Vasilev V, Matrozova J, Elenkova A, Zacharieva S. Clinical characteristics and follow-up of incidentally found adrenal tumours- results from a single tertiary centre. Cent Eur J Med. 2014;9(2):292-301.

  10. Terzolo M, Stigliano A, Chiodini I. AME Position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164:851-70.

  11. Eisenhofer G, Goldstein D, Walther M, Friberg P, Lenders J, Keiser H, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endoc Metab. 2003;88:2656-66.

  12. Funder J, Carey R, Fardella C, Gomez-Sanchez C, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endoc Metab. 2008;93:3266-81.

  13. Zeiger M, Thompson G, Duh Q, Hamrahian A, Angelos P, Elaraj D, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endoc Pract. 2009;15:1-20.

  14. Myśliwiec J, Górska M. Primary aldosteronism a common and important problem. A practical guide to the diagnosis and treatment. Polish J Endocrinol. 2012;63(4):324-37.

  15. Tabarin A, Bardet S, Bertherat J, Dupas B, Chabre O, Hamoir E, et al. Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus. Ann Endocrinol. 2008;69:487-500.

  16. Aron D, Terzolo M, Cawood TJ. Adrenal incidentalomas. Best Pract Res Clin Endocrinol Metab. 2012;26:69-82.

  17. Fontana D, Porpiglia F, Destefanis P, Fiori C, Ali A, Terzolo M, et al. What is the role of ultrasonography in the follow up of adrenal incidentalomas? Urology. 1999;54:612-6.

  18. Hamrahian A, Ioachimescu A, Remer E, Motta-Ramirez G, Bogabathina H, Levin HS, et al. Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from non adenomas: Cleveland clinic experience. J Clin Endocrinol Metab. 2005;90:871-7.

  19. Papierska L,Cichocki A, Sankowski A, Ćwikła J. Adrenal incidentaloma imagingthe first step in therapeutic management. Pol J Radiol. 2013;78(4):47-55.

  20. Young WF. The incidentally discovered adrenal mass. NEJM. 2007;356:601-10.

  21. Podgórska J, Cieszanowski A, Bednarczuk T. Adrenal imaging. Pol J Endocrinol. 2012;63(1):71-81.

  22. Siegelman E. Adrenal MRI. Techniques and clinical applications. J Mag Resonance Imaging. 2012;36:272-85.

  23. Gross M, Shapiro B, Francis I, Glazer G, Bree R, Arcomano M, et al. Scintigrafic evaluation of clinically silent adrenal masses. J Nucl Med. 1994;35:1145-52.

  24. Groussin L, Bonardel G, Silvera S, Tissier F, Coste J, Abiven G, et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab. 2009;94:1713-22.

  25. Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H, et al. [123 I] Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endoc Metab. 2008;93:2358-65.

  26. Boland G, Blake M, Hahn P, Mayo-Smith W. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiol. 2008;249:756-75.

  27. Berland L, Silverman S, Gore R, Mayo-Smith W, Megibow A, Yee J, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol. 2010;7:754-73.

  28. Casola G, Nicolet V, Van Sonnenberg E, Withers C, Bretagnolle M, Saba RM, et al. Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy. Radiol. 1986;159:733-5.

  29. Lentschener C, Gaujoux S, Tesniere A, Dousset B. Point of controversy: perioperative care of patients undergoing pheochromocytoma removal-time for a reappraisal? Eur J Endocrinol. 2011;165:365-73.

  30. Sarathi V, Lila A, Bandgar T, Menon P, Shah N. Pheochromocytoma and pregnancy: a rare but dangerous combination. Endoc Pract. 2009;26:1-21.

  31. Shen W, Lee J, Kebebew E, Clark O, Duh Q. Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases. Arch Surg. 2006;141:771-4.

  32. Cui X, Yang L, Li J, Bu S,1 Wei Q, An Z, et al. Perioperative endocrine therapy for patients with Cushing’s syndrome undergoing retroperitoneal laparoscopic adrenalectomy. Inter J Endocrinol [serie en Internet]. 2012 Article ID 983965, doi:10.1155/2012/983965 [citado 4 de septiembre de 2014]. Disponible en: http://www.hindawi.com/journals

  33. Ulchaker JC, Goldfarb DA, Bravo EL & Novick AC. Successful outcomes in pheochromocytoma surgery in the modern era. J Urology. 1999:161:764-7.

  34. Witteles R, Kaplan E, Roizen M. Safe and cost-effective preoperative preparation of patients with pheochromocytoma. Anesth Analg. 2000;91:302-4.

  35. Lebuffe G, Dosseh E, Tek G, Tytgat H, Moreno S, Tavernier B, et al. The effect of calcium channel blockers on outcome following the surgical treatment of pheochromocytomas and paragangliomas. Anaesth. 2005;60:439-44.

  36. Halpern N, Goldberg M, Neely C, Sladen R, Oldberg J, Floyd J, et al. Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Critical Care Med. 1992;20:1637-43.

  37. Kim D, Matsui C, Gozani J, Mathias L. Phaeochromocytoma anaesthetic management. O J Anest. 2013;3:152-5.

  38. Kinney M, Narr B, Warner M. Perioperative management of pheochromocytoma. J Cardioth Vasc Anesth. 2002;16:359-69.

  39. Sibal L, Jovanovic A, Agarwal S, Peaston R, James R, Lennard T, et al Phaeochromocytomas presenting as acute crises after beta blockade therapy. Clin Endoc. 2006;65:186-90.

  40. Papadopoulos D, Mourouzis I, Thomopoulos C, Makris T, Papademetriou V. Hypertension crisis. Blood Pressure. 2010;19:328-36.

  41. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91:2027-37.

  42. Grossrubatscher E, Vignati F, Possa M, Loli P. The natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation. J Endocrinol Invest. 2001;24: 846-55.

  43. Bulow B, Jansson S, Juhlin C, Steen L, Thoren M, Wahrenberg H, et al. Adrenal incidentaloma -follow-up results from a Swedish prospective study. Eur J Endocrinol. 2006;154:419-23.

  44. Bernini GP, Moretti A, Oriandini C, Bardini M, Taurino C, Salvetti A. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. British J Cancer. 2005;92:1104-9.

  45. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A. Management of adrenal incidentaloma. Best Practice and Research. Clin Endocrinol Metab. 2009;23:233-3.

  46. Chiodini I. Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol. 2011;96:1223-36.




2020     |     www.medigraphic.com